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Introduction High intrapatient variability (IPV) in 
tacrolimus trough levels has been shown to be associated 
with higher rates of renal transplant failure. There is no 
consensus on what level of IPV constitutes a risk of graft 
loss. The establishment of such a threshold could help to 
guide clinicians in identifying at-risk patients to receive 
targeted interventions to improve IPV and thus outcomes.
Methods and analysis A multicentre Transplant 
Audit Collaborative has been established to conduct 
a retrospective study examining tacrolimus IPV and 
renal transplant outcomes. Patients in receipt of a renal 
transplant at participating centres between 2009 and 2014 
and fulfilling the inclusion criteria will be included in the 
study. The aim is to recruit a minimum of 1600 patients 
with follow-up spanning at least 2 years in order to 
determine a threshold IPV above which a renal transplant 
recipient would be considered at increased risk of graft 
loss. The study also aims to determine any national or 
regional trends in IPV and any demographic associations.
Ethics and dissemination Consent will not be sought 
from patients whose data are used in this study as no 
additional procedures or information will be required from 
participants beyond that which would normally take place 
as part of clinical care. The study will be registered locally 
in each participating centre in line with local research and 
development protocols. It is anticipated that the results of 
this audit will be disseminated locally, in participating NHS 
Trusts, through national and international meetings and 
publications in peer-reviewed journals.
InTRoduCTIon
The addition of calcineurin inhibitors (CNIs) 
as maintenance immunosuppressants has 
improved renal transplant 1-year survival 
rates since the 1980s.1 Tacrolimus emerged 
as a viable alternative to ciclosporin in the 
1990s.1 In 2005, a meta-analysis was published 
on randomised trial data comparing 
tacrolimus and ciclosporin as primary 
immunosuppressants in renal transplant, 
observing a 44% reduction in death-censored 
graft loss with tacrolimus over ciclosporin.2 In 
2007, the Symphony Study reported favour-
able graft survival and function, and reduced 
biopsy-proven rejection with low-dose tacro-
limus over low-dose ciclosporin, sirolimus or 
standard-dose tacrolimus.3
CNIs have a narrow therapeutic index: 
too little exposure places a transplant recip-
ient at increased risk of acute rejection and 
donor-specific antibody formation. Too much 
exposure and a transplant recipient is placed 
at increased risk of malignancy, infection, 
nephrotoxicity and unacceptable side effects 
such as tremor.4–7
Strengths and limitations of this study
 ► This is a multicentre collaborative study composed 
of units across the UK which are both transplant 
centres and referring nephrology units.
 ► The sample size will be the largest investigating IPV 
to date.
 ► The study uses a unified method across all 
participating centres, which will enable meaningful 
comparison between centres.
 ► The study investigates retrospective data and 
requires a lengthy follow-up period which will lead 
to some exclusions.
 ► There will be minor local variations in the laboratory 
assay that cannot be corrected for in the IPV 
calculations.
 ► Confounding factors such as geographical bias, 
repatriation as a cause of lost to follow-up, under-
representation of poorly compliant patients who do 
not attend appointments, frequency of sampling and 
temporary medications are beyond the scope of this 
study.
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Trough levels are used as a proxy for oral bioavailability 
of CNIs and vary both between patients (interpatient 
variability) and for an individual over time (intrapatient 
variability, IPV). Between individuals, age, gender, ethnicity, 
body mass index, genetic polymorphisms in CYP3A5 and 
CYP3A4, drug interactions, adherence, liver function and 
lifestyle choices account for the differences. Similarly, IPV 
is affected by adherence, gastrointestinal metabolism and 
motility, diarrhoea, food and drug interactions, synchro-
nicity of dose administration and blood test and variability 
of the laboratory assay.8–15
An emerging body of evidence is being established 
indicating favourable graft function, survival and fewer 
rejection episodes up to 1 year post-transplant for patients 
demonstrating low IPV.16–18 Similarly, high IPV has been 
associated with poorer outcomes and graft survival.19 20 
Donor age and previous transplants appear to be risk 
factors for a high IPV.18 However, little data exists on the 
long-term impact of high IPV and studies have not yet 
been able to draw conclusions about risk thresholds of 
variability because of limitations in sample size.
objectives
 ► To establish important baseline data about national 
and regional trends in IPV
 ► To investigate demographic associations and other 
characteristics for patients in high and low variability 
groups
 ► To establish whether there exists a ‘danger’ threshold 
for IPV, above which a patient is deemed at risk of 
graft loss or dysfunction, so they can then be targeted 
for intervention prior to organ damage or failure
Outcomes
Primary outcomes: Recent 12 months’ IPV, IPV months 
6–12, change in IPV.
Secondary outcomes: Ethnicity, recipient age, change in 
IPV, previous transplants, DR mismatch, graft function, 
graft survival, gender.
Confounders
We acknowledge the potential for confounding factors 
that are outside the scope of this study to address. These 
include frequency of tacrolimus level sampling (and the 
reasons why this might be increased) and conversely 
under-representation of poorly compliant patients who 
do not attend appointments. These confounders may be 
affected by hospital admissions, temporary medication 
use (such as oral antibiotics) and those patients with a 
modified tacrolimus target.
METhodS And AnAlySIS
A multicentre transplant audit collaborative (TAC) has 
been established to conduct a retrospective study exam-
ining tacrolimus IPV and renal transplant outcomes. It 
is the first collaborative of its kind, facilitating the devel-
opment of this largest study examining IPV to date. 
TAC is composed of junior doctors with an interest in 
nephrology and/or transplantation. It is supported by 
Consultant physicians and surgeons in these fields to 
undertake research and audit projects related to trans-
plantation. Any UK NHS Trust involved in the aftercare 
of renal transplant recipients is eligible to register for 
this study providing they have a transplant or nephrology 
doctor willing to enrol in the TAC.
Patient selection
Patients in receipt of a renal transplant at participating 
centres between 2009 and 2014 and fulfilling the inclu-
sion criteria will be included in the study (table 1). To 
be enrolled, patients are required to have follow-up span-
ning at least 2 years in order to determine a threshold IPV 
above which a renal transplant recipient would be consid-
ered at increased risk of graft loss.
Sample size
A large sample size is needed to provide meaningful 
numbers to establish variability risk cut-offs. It is estimated 
that a minimum of eight UK-based centres will participate 
in the study. If each centre, on average, supplies data for 
200 patients, a minimum dataset of 1600 patients will be 
achieved.
It is, however, recognised that there will be a significant 
variation between the numbers of eligible patients avail-
able to each centre (tertiary transplant units will naturally 
have access to larger numbers that referring District 
General Hospitals). The set number of 200, therefore, is 
Table 1 Inclusion/exclusion criteria
Inclusion criteria Exclusion criteria
Age ≥18 years at time 
of transplant
Age ≤17 years at time of transplant
A functioning graft* 
at 2 years







Modified release preparation at any
Only during study 
period




Other primary immunosuppressant 
(eg, ciclosporin, sirolimus, other non-
steroid)
Alive minimum 
2 years following 
transplant
Pregnancy at any point during study 
period
Death prior to 2 years following 
transplant
Non-standard transplant (ABO 
or HLA incompatible; requiring 
desensitisation)
Patients with fewer than four 
tacrolimus trough levels for T1 and T2
T1, 6–12 months post-transplant; T2, most recent 12 months.
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only to be used as a guide and it is recognised that this 
may not be achievable for smaller, secondary nephrology 
units. Similarly, we welcome larger numbers from any 
centre able to do so.
data collection and information governance
TAC has established a standard minimum dataset (see 
box 1) which each site will use as the basis for data 
collection. A template database will be provided to a 
representative of the study team from each NHS Trust 
participating in the study. This database will be password 
protected and held on secure local Trust servers. All data 
should be entered onto this database – the use of hard 
copy proformas associated with this audit is discouraged 
to avoid breaching data protection policies.
The data collection database will be anonymised and will 
contain no patient identifiable data. Each hospital will be 
issued with patient study identifiers for all patients included 
in the study. A separate password-protected spreadsheet 
of the study identifiers with the corresponding hospital 
numbers should be securely stored locally by each partici-
pating centre for local reference only should there be any 
difficulties or queries regarding data collection.
The anonymised master database will be compiled by 
a dedicated, named member of the collaborative. It will 
be shared with all members of TAC using secure NHS 
email only (either local Trust email or  NHS. net) and will 
be held on secure, password-protected Trust servers only.
Data collection has been under way since March 2017 
and is scheduled for completion in September 2017. A 
period of data analysis will then follow until December 
2017 at which time the results will be disseminated as 
detailed in the Ethics and Dissemination section below.
data analysis
Studies have shown that high IPV is associated with poorer 
renal transplant outcomes17 but no research group has yet 
established or described an IPV level at which the risk of 
such outcomes is significantly increased. With our large 
sample size, we will be able to stratify our group into quar-
tiles or quintiles based on IPV, enabling us to compare 
outcomes between the groups.
IPV will be calculated using the mean absolute devi-
ation as described by Shuker et al.18 Individual subjects 
will be stratified into groups based on observed variability 
during T1. Intergroup comparisons will be made using 
both univariate and multivariate analyses for the clinically 
relevant end points including graft loss, graft dysfunction 
(assessed by eGFR and new onset proteinuria) and biop-
sy-proven rejection episodes. The univariate predictive 
value of T1 IPV for these outcomes will be evaluated by 
receiver operator curve assessment.
Categorical variables will be compared using Χ2 and 
Fisher’s exact test where appropriate. Continuous vari-
ables will be assessed using T test for parametric and 
Mann-Whitney U test for non-parametric data.
Multivariate analysis will use Cox regression survival 
analysis to compare event-free survival, corrected for 
potential confounders including age, gender and 
ethnicity. Where there is loss to follow-up after the 2-year 
period, data will be censored according to last known 
status at the time of last creatinine or tacrolimus level 
(whichever is the latter).
Permissions and registration
Each participating centre will be expected to complete 
a site registration form. A named member of TAC from 
each participating centre will be responsible for gaining 
all necessary local Trust permissions and study registra-
tions as required by local Research and Development and 
Audit offices.
Consent will not be sought from patients whose data 
are used in this study as no additional procedures or 
information will be required from participants beyond 
that which would normally take place as part of clinical 
care. The findings of the study are not expected to impact 
on individual patient care.
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Box 1 Minimum dataset
 ► Data set
 ► Date of transplant
 ► Recipient and donor ages
 ► Gender
 ► Ethnicity
 ► Primary renal diagnosis
 ► Previous transplants
 ► Mismatch grade (A, B, DR)
 ► Type of donor
 ► eGFR at the end of T1 and T2
 ► Creatinine at 12 months and at the end of T2
 ► All tacrolimus trough levels during T1 and T2
 ► Urinary protein creatinine ratio at the of end T1 and T2
 ► Graft failure
 ► Delayed graft function
 ► Tacrolimus dosing at month 12 and at the end of T2
 ► Other immunosuppression at both T1 and T2:
 ► Steroid Y/N;
 ► MMF Y/N;
 ► Azathioprine Y/N
 ► Induction agent
 ► De  novo donor-specific antibody status post-transplant and level 
(mean fluorescence intensity)
 ► Biopsy-proven acute rejection
 ► Death
T1, 6–12 months post-transplant; T2, most recent 12 months.
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